Elsevier and Roche Collaborate To Integrate Proprietary Chemistry Data In Reaxys®
FRANKFURT, Germany, October 1, 2012 /PRNewswire/ –
Roche researchers expected to benefit from increased discoverability of
in-house chemistry content, integrated and unified with externally validated content,
directly retrievable in Reaxys
Elsevier [http://www.elsevier.com ] today announced the integration of Roche propriety
reaction information within Reaxys, which will run on Roche’s infrastructure and inside
the Roche firewall to provide high performance and security. Roche chemistry information
will be securely searchable and discoverable by Roche scientists through the Reaxys user
interface. The incorporation and discoverability of Roche proprietary information in
Reaxys is anticipated to significantly improve Roche scientists’ productivity.
With this development Roche researchers will be able to launch a single search in
Reaxys across integrated internal data and experimental data published in journals and
patents, with results unified and organised in a context directly relevant to the
researcher workflow. The announcement comes after many months of collaboration between
teams from Roche and Reaxys.
“We have been seeking to improve the discoverability of our in-house proprietary
content, while at the same time avoiding investing in and maintaining an entirely new
internally or externally developed system,” explained Sven-Olaf Vogt, Global Head
Scientific Information Management at Roche. “Working with the Reaxys team was a logical
choice given the widespread adoption of Reaxys at Roche and the knowledge of the Reaxys
team in chemistry content.”
Mark van Mierle, Managing Director of Elsevier’s Pharma and Biotech Group, added, “Our
collaboration with Roche shows how we can work together with customers to serve scientist
needs. Researchers want seamless, unified data streams, delivered through highly intuitive
workflow tools. Our work with Roche responds directly to those needs and enables
researchers to innovate more effectively by accessing data they need, through a
Reaxys(R) is a workflow solution for research chemists. Offering a wealth of
experimentally validated information, Reaxys(R) combines reaction and substance data in
organic, organometallic, inorganic and physical chemistry with synthesis planning.
Researchers can get the information they need in a single overview, from source
publications carefully selected for their importance and relevance to research chemists.
Elsevier continues to engage with the chemistry community to ensure that Reaxys(R)
continues to reflect how chemists think and work. https://www.reaxys.com/info
Reaxys (R) and the Reaxys trademark are owned and protected by Reed Elsevier
Properties SA and used under license.
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], ClinicalKey
[http://www.clinicalkey.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Tom Reller Vice President, Global Corporate Relations Elsevier +1-215-239-3508 email@example.com